Neuroprotection and Precision Therapy in Glaucoma

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue of Vision titled “Neuroprotection and Precision Therapy in Glaucoma.” Traditionally, the primary goal of glaucoma therapy has been the reduction and adequate control of intraocular pressure (IOP), which remains the most important modifiable risk factor for disease progression. However, contemporary therapeutic strategies increasingly recognize that effective glaucoma management should extend beyond IOP reduction alone. In this context, neuroprotection has emerged as a central concept in glaucoma research and clinical practice. Neuroprotective strategies aim to preserve retinal ganglion cells and prevent or delay the neurodegenerative processes that ultimately lead to visual impairment.

Over the past decade, substantial progress has been made in both pharmacological and surgical treatment modalities for glaucoma. Novel medications, minimally invasive glaucoma surgery (MIGS), and refined surgical techniques have expanded the therapeutic landscape and improved the range of available treatment options. In parallel, advances in ocular imaging, particularly optical coherence tomography (OCT) of the anterior and posterior segments, have revolutionized the diagnosis and monitoring of glaucoma. Beyond its established role in clinical diagnostics, OCT imaging can also provide valuable insights into structural and potentially cellular alterations associated with disease onset and progression.

These developments underscore the growing importance of precision medicine in glaucoma care, where therapeutic decisions are increasingly tailored to the individual characteristics, risk profiles, and disease stages of each patient. For this Special Issue, we welcome the submission of original research articles and comprehensive review papers addressing neuroprotective mechanisms, innovative diagnostic approaches, and precision therapeutic strategies in glaucoma. Contributions that advance our understanding of disease mechanisms or highlight novel treatment paradigms are particularly encouraged.

Prof. Dr. Jan Darius Unterlauft
Dr. Somar Hasan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vision is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.